Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

First-in-human clinical series of a novel conformable large-lattice pulsed field ablation catheter for pulmonary vein isolation

VY. Reddy, E. Anter, P. Peichl, G. Rackauskas, J. Petru, M. Funasako, JS. Koruth, G. Marinskis, M. Turagam, A. Aidietis, J. Kautzner, A. Natale, P. Neuzil

. 2024 ; 26 (4) : . [pub] 20240330

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články, multicentrická studie, práce podpořená grantem, klinické zkoušky

Perzistentní odkaz   https://www.medvik.cz/link/bmc24014522

Grantová podpora
Affera, Inc

AIMS: Pulsed field ablation (PFA) has significant advantages over conventional thermal ablation of atrial fibrillation (AF). This first-in-human, single-arm trial to treat paroxysmal AF (PAF) assessed the efficiency, safety, pulmonary vein isolation (PVI) durability and one-year clinical effectiveness of an 8 Fr, large-lattice, conformable single-shot PFA catheter together with a dedicated electroanatomical mapping system. METHODS AND RESULTS: After rendering the PV anatomy, the PFA catheter delivered monopolar, biphasic pulse trains (5-6 s per application; ∼4 applications per PV). Three waveforms were tested: PULSE1, PULSE2, and PULSE3. Follow-up included ECGs, Holters at 6 and 12 months, and symptomatic and scheduled transtelephonic monitoring. The primary and secondary efficacy endpoints were acute PVI and post-blanking atrial arrhythmia recurrence, respectively. Invasive remapping was conducted ∼75 days post-ablation. At three centres, PVI was performed by five operators in 85 patients using PULSE1 (n = 30), PULSE2 (n = 20), and PULSE3 (n = 35). Acute PVI was achieved in 100% of PVs using 3.9 ± 1.4 PFA applications per PV. Overall procedure, transpired ablation, PFA catheter dwell and fluoroscopy times were 56.5 ± 21.6, 10.0 ± 6.0, 19.1 ± 9.3, and 5.7 ± 3.9 min, respectively. No pre-defined primary safety events occurred. Upon remapping, PVI durability was 90% and 99% on a per-vein basis for the total and PULSE3 cohort, respectively. The Kaplan-Meier estimate of one-year freedom from atrial arrhythmias was 81.8% (95% CI 70.2-89.2%) for the total, and 100% (95% CI 80.6-100%) for the PULSE3 cohort. CONCLUSION: Pulmonary vein isolation (PVI) utilizing a conformable single-shot PFA catheter to treat PAF was efficient, safe, and effective, with durable lesions demonstrated upon remapping.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24014522
003      
CZ-PrNML
005      
20240905134051.0
007      
ta
008      
240725s2024 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1093/europace/euae090 $2 doi
035    __
$a (PubMed)38584468
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Reddy, Vivek Y $u Department of Cardiology, Icahn School of Medicine at Mount Sinai, One Gustave Levy Place, Box 1030, New York, NY, USA $u Department of Cardiology, Homolka Hospital, Prague, Czech Republic $1 https://orcid.org/0000000256384993
245    10
$a First-in-human clinical series of a novel conformable large-lattice pulsed field ablation catheter for pulmonary vein isolation / $c VY. Reddy, E. Anter, P. Peichl, G. Rackauskas, J. Petru, M. Funasako, JS. Koruth, G. Marinskis, M. Turagam, A. Aidietis, J. Kautzner, A. Natale, P. Neuzil
520    9_
$a AIMS: Pulsed field ablation (PFA) has significant advantages over conventional thermal ablation of atrial fibrillation (AF). This first-in-human, single-arm trial to treat paroxysmal AF (PAF) assessed the efficiency, safety, pulmonary vein isolation (PVI) durability and one-year clinical effectiveness of an 8 Fr, large-lattice, conformable single-shot PFA catheter together with a dedicated electroanatomical mapping system. METHODS AND RESULTS: After rendering the PV anatomy, the PFA catheter delivered monopolar, biphasic pulse trains (5-6 s per application; ∼4 applications per PV). Three waveforms were tested: PULSE1, PULSE2, and PULSE3. Follow-up included ECGs, Holters at 6 and 12 months, and symptomatic and scheduled transtelephonic monitoring. The primary and secondary efficacy endpoints were acute PVI and post-blanking atrial arrhythmia recurrence, respectively. Invasive remapping was conducted ∼75 days post-ablation. At three centres, PVI was performed by five operators in 85 patients using PULSE1 (n = 30), PULSE2 (n = 20), and PULSE3 (n = 35). Acute PVI was achieved in 100% of PVs using 3.9 ± 1.4 PFA applications per PV. Overall procedure, transpired ablation, PFA catheter dwell and fluoroscopy times were 56.5 ± 21.6, 10.0 ± 6.0, 19.1 ± 9.3, and 5.7 ± 3.9 min, respectively. No pre-defined primary safety events occurred. Upon remapping, PVI durability was 90% and 99% on a per-vein basis for the total and PULSE3 cohort, respectively. The Kaplan-Meier estimate of one-year freedom from atrial arrhythmias was 81.8% (95% CI 70.2-89.2%) for the total, and 100% (95% CI 80.6-100%) for the PULSE3 cohort. CONCLUSION: Pulmonary vein isolation (PVI) utilizing a conformable single-shot PFA catheter to treat PAF was efficient, safe, and effective, with durable lesions demonstrated upon remapping.
650    _2
$a lidé $7 D006801
650    12
$a venae pulmonales $x chirurgie $7 D011667
650    12
$a fibrilace síní $x chirurgie $x patofyziologie $x diagnóza $7 D001281
650    12
$a katetrizační ablace $x metody $x přístrojové vybavení $7 D017115
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé středního věku $7 D008875
650    _2
$a senioři $7 D000368
650    _2
$a výsledek terapie $7 D016896
650    12
$a recidiva $7 D012008
650    12
$a srdeční katétry $7 D062906
650    _2
$a design vybavení $7 D004867
650    _2
$a elektrofyziologické techniky kardiologické $7 D022062
650    _2
$a časové faktory $7 D013997
650    _2
$a srdeční frekvence $7 D006339
650    _2
$a akční potenciály $7 D000200
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a práce podpořená grantem $7 D013485
655    _2
$a klinické zkoušky $7 D016430
700    1_
$a Anter, Elad $u Division of Cardiovascular Medicine, Shamir Medical Center, Be'er Yaakov, Tel Aviv, Israel $1 https://orcid.org/0000000281992288
700    1_
$a Peichl, Petr $u Department of Cardiology, Institute for Clinical and Experimental Medicine-IKEM, Prague, Czech Republic $1 https://orcid.org/0000000256250071 $7 xx0092197
700    1_
$a Rackauskas, Gediminas $u Department of Cardiology, Vilnius University, Vilnius, Lithuania $1 https://orcid.org/0000000332724380
700    1_
$a Petru, Jan $u Department of Cardiology, Homolka Hospital, Prague, Czech Republic
700    1_
$a Funasako, Moritoshi $u Department of Cardiology, Homolka Hospital, Prague, Czech Republic $1 https://orcid.org/0000000216203924
700    1_
$a Koruth, Jacob S $u Department of Cardiology, Icahn School of Medicine at Mount Sinai, One Gustave Levy Place, Box 1030, New York, NY, USA $1 https://orcid.org/0000000222218372
700    1_
$a Marinskis, Germanas $u Department of Cardiology, Vilnius University, Vilnius, Lithuania
700    1_
$a Turagam, Mohit $u Department of Cardiology, Icahn School of Medicine at Mount Sinai, One Gustave Levy Place, Box 1030, New York, NY, USA
700    1_
$a Aidietis, Audrius $u Department of Cardiology, Vilnius University, Vilnius, Lithuania
700    1_
$a Kautzner, Josef $u Department of Cardiology, Institute for Clinical and Experimental Medicine-IKEM, Prague, Czech Republic $1 https://orcid.org/0000000216326182 $7 xx0037112
700    1_
$a Natale, Andrea $u Texas Cardiac Arrhythmia Institute, St. David's Medical Center, Austin, TX, USA $u Department of Biomedicine and Prevention, Division of Cardiology, University of Tor Vergata, Rome, Italy $1 https://orcid.org/000000016601944X
700    1_
$a Neuzil, Petr $u Department of Cardiology, Homolka Hospital, Prague, Czech Republic $1 https://orcid.org/0000000343348165
773    0_
$w MED00149837 $t Europace $x 1532-2092 $g Roč. 26, č. 4 (2024)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38584468 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240725 $b ABA008
991    __
$a 20240905134045 $b ABA008
999    __
$a ok $b bmc $g 2143966 $s 1226388
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 26 $c 4 $e 20240330 $i 1532-2092 $m Europace $n Europace $x MED00149837
GRA    __
$p Affera, Inc
LZP    __
$a Pubmed-20240725

Najít záznam

Citační ukazatele

Možnosti archivace